The New Reality of Peptide Analysis
Kelly Broster of Thermo Fisher Scientific explains why GLP-1 peptides are exposing the limits of traditional analytical workflows
-
By
-
James Strachan
-
June 1, 2026
-
Clinical Scorecard: The New Reality of Peptide Analysis
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Characterization of structural microheterogeneity and impurities in peptides. [Ensure direct sourcing] |
| Target Population | |
| Care Setting | |
Key Highlights
- Peptide therapeutics require deep structural characterization beyond simple purity metrics.
- GLP-1 analogs illustrate the limitations of small-molecule analytical assumptions.
- Orthogonal analytics like HRAM MS and UHPLC are essential for resolving peptide variants.
- Detection of low-concentration impurities is critical for maintaining biological activity. [Remove unless sourced]
- Workflows must balance high-end characterization with practical deployability in QC.
Guideline-Based Recommendations
Diagnosis
- Assess structural microheterogeneity and impurities in peptide therapeutics. [Ensure direct sourcing]
Management
- Utilize HRAM MS and UHPLC for comprehensive impurity profiling. [Ensure direct sourcing]
Monitoring & Follow-up
- Implement targeted assays to monitor critical quality attributes (CQAs). [Ensure direct sourcing]
Risks
- Small impurities can significantly impact potency, stability, and immunogenicity. [Ensure direct sourcing]
Patient & Prescribing Data
Not specified in the source material.
Focus on understanding structural variants and their impacts on therapeutic efficacy. [Clarify sourcing]
Clinical Best Practices
- Shift from purity-centric to structure-and-heterogeneity-centric analytical approaches. [Remove unless sourced]
- Employ complementary MS/MS techniques to avoid blind spots in impurity characterization. [Remove unless sourced]
- Ensure analytical methods are robust, validated, and scalable for routine QC. [Remove unless sourced]
Related Resources & Content
